High Immune Response Rates and Decreased Frequencies of Regulatory T Cells in Metastatic Renal Cell Carcinoma Patients after Tumor Cell Vaccination

Table 1 Patient characteristics, vaccination course and clinical outcome.

ID	Prognostic score^a	Therapy before study entry	Site(s) of metastases	2.5 × 10⁶ cells	10 × 10⁶ cells	40 × 10⁶ cells	Site(s) of progression	TTP (wks)	Survival (wks)
MR-1	2	—	Lung, bone	4	1	—	Bone, brain^b	7	31
MR-2	1	Cytokine,^c G250^d	Lung, LN	4	4	2	Pleura,^b bone^b	23	79
MR-4	1	Cytokine, G250	Lung, LN, adrenal gland	4	4	2	Lung	35	68
MR-5	1	Cytokine	Lung	4	4	2	LN,^b adrenal gland^b	7	76
MR-6	2	—	Bone	—	4	2	Bone	6	18
MR-7	1	—	LN, pleura, local recurrence	—	4	2	Pleura, liver^b	28	84
MR-9	2	Cytokine	Lung, pancreas	—	4	2	Pancreas, liver^b	39	79
MR-10	0	Sorafenib	Lung	4	4	2	Brain^b	23	55
MR-11	2	G250	Lung, LN, spinal cord	4	4	—	—	SD (7)^e	17^f
MR-13	1	DC, multi-peptide vaccine	Lung, LN, brain	4	4	2	Brain	33	104
MR-14	2	Multi-peptide vaccine	Lung, LN, adrenal gland	4	4	2	LN	35	107
MR-15	1	Cytokine	Lung, LN	4	4	2	—	SD (131)^e	151 (alive)

TTP time to progression; LN, lymph node; DC, dendritic cell; SD, stable disease.
^aPalmer score from 0 (very low risk) to 3 (high risk) based on performance status, number of metastatic sites and the time from first diagnosis to study entry (14).
^bNew metastases.
^cCytokine: IFN-α, IL-2, 5-fluorouracil.
^dG250: monoclonal antibody directed against carbonic anhydrase IX.
^eSD (7) and SD (131) indicate stable disease at wks 7 and 131, respectively.
^fDeath of patient MR-11, not related to therapy or disease.

ISSN: 1528-3658